Sona Nanotech Inc. (CSE: SONA) (OTCQB: SNANF) (the "Company" or "Sona") is pleased to announce that it has closed its non-brokered private placement that was announced on September 5, 2024 with the issuance of 6,575,000 common shares (each, a "Share") at $0.25 per share (the "Financing") for gross proceeds of $1,643,750. One Insider of Sona subscribed for 400,000 of those common shares for gross proceeds of $100,000. The subscription to the Financing by one insider of the Issuer is a related party transaction for the purposes of Multilateral Instrument 61-101 Protection of Minority Security Holders in Special Transactions ("MI 61-101"). The Issuer is relying on exemptions from the formal valuation and minority shareholder approval requirements provided under sections 5.5(a) and 5.7(1)(a) of MI 61-101 on the basis that the fair market value of the insider's subscription does not exceed 25% of the market capitalization of the Issuer as determined in accordance with MI 61-101. This Financing, together with Sona's financing that closed on September 5, 2024, totals gross proceeds of $3,143,750.
- AustraliaNorth AmericaWorld
Investing News NetworkYour trusted source for investing success
- Lithium Outlook
- Oil and Gas Outlook
- Gold Outlook Report
- Uranium Outlook
- Rare Earths Outlook
- All Outlook Reports
- Top Generative AI Stocks
- Top EV Stocks
- Biggest AI Companies
- Biggest Blockchain Stocks
- Biggest Cryptocurrency-mining Stocks
- Biggest Cybersecurity Companies
- Biggest Robotics Companies
- Biggest Social Media Companies
- Biggest Technology ETFs
- Artificial Intellgience ETFs
- Robotics ETFs
- Canadian Cryptocurrency ETFs
- Artificial Intelligence Outlook
- EV Outlook
- Cleantech Outlook
- Crypto Outlook
- Tech Outlook
- All Market Outlook Reports
- Cannabis Weekly Round-Up
- Top Alzheimer's Treatment Stocks
- Top Biotech Stocks
- Top Plant-based Food Stocks
- Biggest Cannabis Stocks
- Biggest Pharma Stocks
- Longevity Stocks to Watch
- Psychedelics Stocks to Watch
- Top Cobalt Stocks
- Small Biotech ETFs to Watch
- Top Life Science ETFs
- Biggest Pharmaceutical ETFs
- Life Science Outlook
- Biotech Outlook
- Cannabis Outlook
- Pharma Outlook
- Psychedelics Outlook
- All Market Outlook Reports
MAP Test
Sona Nanotech Closes Private Placement Financing to Raise $1,643,750 in Gross Proceeds
As previously disclosed, Sona intends to use the net proceeds of the Financing for advancing studies to support regulatory permission for an international, multi-site, first-in-human clinical trial, further research and development of its Targeted Hyperthermia TherapyTM ("THT"), as well as for general working capital purposes.
Numus Capital Corp. (the "Finder"), a registered Exempt Market Dealer, acted as exclusive finder for the Financing. In connection with the private placement, Sona paid the Finder a cash commission of $91,813 and issued 367,250 non-transferable share purchase warrants (the "Finder Warrants"). Each Finder Warrant entitles the Finder to acquire one Share at an exercise price of $0.25 until September 23, 2026. The Finder is a related party to Sona, a director of Sona being indirectly a principal shareholder of the Finder, as well such director of Sona also being a director and officer of the Finder.
All securities issued pursuant to the Financing will be subject to a hold period until January 24, 2025.
Contact:
David Regan, CEO
+1-902-536-1932
david@sonanano.com
About Sona Nanotech Inc.
Sona Nanotech, a nanotechnology life sciences company, is developing Targeted Hyperthermia™, a photothermal cancer therapy, which uses therapeutic heat to treat solid cancer tumors. The heat is delivered to tumors by infrared light that is absorbed by Sona's gold nanorods in the tumor and re-emitted as heat. Therapeutic heat (41-48°C) stimulates the immune system, shrinks tumors, inactivates cancer stem cells, and increases tumor perfusion - thus enabling drugs to reach all tumor compartments more effectively. Targeted Hyperthermia promises to be safe, effective, minimally invasive, competitive in cost, and a valuable adjunct to drug therapy and other cancer treatments.
Sona has developed multiple proprietary methods for the manufacture of gold nanoparticles which it uses for the development of both cancer therapies and diagnostic testing platforms. Sona Nanotech's gold nanorod particles are cetyltrimethylammonium ("CTAB") free, eliminating the toxicity risks associated with the use of other gold nanorod technologies in medical applications. It is expected that Sona's gold nanotechnologies may be adapted for use in applications, as a safe and effective delivery system for multiple medical treatments, subject to the approval of various regulatory boards, including Health Canada and the FDA.
CAUTIONARY STATEMENT REGARDING FORWARD-LOOKING INFORMATION: This press release includes certain "forward-looking statements" under applicable Canadian securities legislation, including statements regarding the anticipated applications and potential opportunities of Targeted Hyperthermia Therapy, Sona's preclinical and clinical study plans, future patent filings, regulatory submissions and approvals, and its product development plans. Forward-looking statements are necessarily based upon a number of assumptions or estimates that, while considered reasonable, are subject to known and unknown risks, uncertainties, and other factors which may cause the actual results and future events to differ materially from those expressed or implied by such forward-looking statements, including the risk that Sona may not be able to successfully obtain sufficient clinical and other data to submit regulatory submissions, raise sufficient additional capital, secure patents or develop the envisioned therapy, and the risk that THT may not prove to have the benefits currently anticipated. There can be no assurance that such statements will prove to be accurate, as actual results and future events could differ materially from those anticipated in such statements. Accordingly, readers should not place undue reliance on forward-looking statements. Sona disclaims any intention or obligation to update or revise any forward-looking statements, whether as a result of new information, future events or otherwise, except as required by law.
Not for distribution to United States newswire services or for dissemination in the United States.
To view the source version of this press release, please visit https://www.newsfilecorp.com/release/224376
News Provided by Newsfile via QuoteMedia
XRG Investor Presentation FY24
xReality Group Limited (XRG) specialises in building and operating immersive XR products and experiences that enhance lives. xReality Group’s portfolio includes physical and digital simulation used across the enterprise, defence and consumer markets. Using technology we create experiences without the physical limitations found in the real world.
XR stands for Extended Reality and is a catch-all term for Virtual Reality (VR), Augmented Reality (AR) and Mixed Reality (MR). Extended Reality combines physical and digital simulation for both consumer and enterprise market segments. The XR category is growing rapidly with the market predicted to grow from US $26B in 2020 to US $905B in 2027. Facebook’s parent, Meta, is investing $10Bn US/year alone into accelerating development of the Metaverse.
xReality Group companies include Operator XR, a Defence and Law Enforcement simulation training company, Red Cartel, an XR production company, two Australian iFLY Indoor Skydiving Facilities, and four FREAK Virtual Reality venues.
- xReality Group is an Australian company that specialises in building and operating virtual reality (VR), augmented reality (AR) and physical simulation for the enterprise markets, including law enforcement, defence and consumer leisure market
- The company serves both entertainment and enterprise segments both locally and internationally.
- xReality Group operates four major brands across the end markets including Operator XR which serves our Law Enforcement and Military markets; iFLY Downunder and iFLY Gold Coast (both entertainment and professional); FREAK Entertainment (retail market); and Red Cartel (enterprise).
- Operator XR is the fastest growing segment for the company, focusing on defence and law enforcement agencies across the globe. The total addressable market for Operator XR is valued at US$3.37 billion with the US accounting for nearly 40% of the total market.
Click here for the full ASX Release
This article includes content from xReality Group, licensed for the purpose of publishing on Investing News Australia. This article does not constitute financial product advice. It is your responsibility to perform proper due diligence before acting upon any information provided here. Please refer to our full disclaimer here.
EGY Investor Presentation
Energy Technologies Limited (EGY or the Company) is pleased to present its investor presentation.
Bambach Wires and Cables
- We specialize in providing high-quality electrical cables for a wide range of applications across the Low Voltage (LV), Medium Voltage (MV), and High Voltage (HV) markets. Our comprehensive product offerings cater to diverse industries, with a particular focus on Infrastructure, Renewables, Defence, and Mining sectors.
- Founded in 1936, it is the oldest existing Australian cable manufacturer and 100% owned by Energy Technologies since 2012
- Factory in Rosedale, VIC with sales offices in New South Wales, Western Australia and Victoria
- Blue Chip customer base across Rail and Road, Mining, Construction, Defence and Power and Energy
EGY Overview:
- Bambach has now completed the restructuring of the business.
- The business is now well positioned to offer complete ranges of product groups & solutions into multiple key market segments, via the distribution agreements recently announced and strategic supply lines now secured.
- Factory will continue to manufacture higher margin product lines.
Restructured Business:
- Distribution agreements in market segments with strong tailwinds e.g. utility scale solar farms (the recently announced Gantner agreement, allows the business to offer not only cables, but also control & monitoring equipment as well as hardware & software used in all utility scale solar farms), offshore & onshore wind power generation cables & distribution transmission lines, including subsea transmission cables.
Purchased sales:
- Strategic supply lines have been identified with manufacturers in Turkey, Malaysia & Europe.
Factory:
- The factory will continue to manufacture with a focus on higher margin cables only, substituting lower margin cables via purchased sales.
Click here for the full ASX Release
This article includes content from Energy Technologies Limited, licensed for the purpose of publishing on Investing News Australia. This article does not constitute financial product advice. It is your responsibility to perform proper due diligence before acting upon any information provided here. Please refer to our full disclaimer here.
$5.6M Contract Awarded for US Department of Defense Project
xReality Group Limited (XRG) is pleased to announce it has been awarded a $5.6M AUD contract to deliver a new immersive training capability to the United States Department of Defence. The contract has been awarded to XRG by Acrolect Solutions LLC, DBA Endurance Group, who is serving as prime contractor to the US Department of Defence for the R&D effort.
- The contract scope is to deliver a new immersive training capability and includes supplying Operator XR system licenses along with R&D services.
- The R&D project duration is 20 months commencing 11th September 2024.
- The contract presents opportunities for follow on work.
CEO of XRG, Wayne Jones said“the strategic importance of this project cannot be understated, representing Operator XR’s first major engagement with the US Department of Defence. Operator XR will be jointly developing a cutting edge capability that has the potential to expand into further global agencies as well as the many operational units within the US Defence Force.”
This ASX Release is authorised by the Board of xReality Group Limited.
Click here for the full ASX Release
This article includes content from xReality Group, licensed for the purpose of publishing on Investing News Australia. This article does not constitute financial product advice. It is your responsibility to perform proper due diligence before acting upon any information provided here. Please refer to our full disclaimer here.
Aether Global Announces the Resignation of Director and Appointment of Interim Chief Financial Officer
(TheNewswire)
Vancouver, B.C. September 9, 2024 TheNewswire Aether Global Innovations Corp. ( CSE: AETH ) ( OTCQB: AETHF ) ( Frankfurt: 4XA WKN# A2N8RH) (" Aether Global" " AETH ", or the " Company "), a drone management and automation company announced today the resignation of Zara Kanji from her role as independent Board Director and the appointment of Nancy Boufeas as Interim Chief Financial Officer.
Ms. Kanji will be moving to an advisory position within Aether Global and will continue to provide assistance with the Company's ongoing operations.
"We'd like to thank Zara for her time on the board and her continued support and involvement with Aether" expressed Douglas Smith, Chairman of Aether Global.
Nancy Boufeas, the Company's Corporate Secretary, will act as Interim Chief Financial Officer until such time as the appointment of Aether Global's new Chief Financial Officer which the Company hopes to announce shortly.
The Board will begin a search for a new Independent Director and will notify the market when a replacement has been interviewed and selected.
About Aether Global Innovations Corp.
Aether Global Innovations Corp. is an innovative UAV and drone management and operations services company that focuses in three areas for critical infrastructure and large public and private facilities. These three areas include (i) drone management and surveillance monitoring, (ii) automation and integration for flight planning, new, innovative sensor payloads, stand-alone power source and (iii) drone base station infrastructure and technology for autonomous self-landing, power charging, and take off. www.aethergic.com
ON BEHALF OF THE BOARD OF DIRECTORS
Douglas Smith, Chairman of the Board
Aether Global Innovations Corp.
info@aethergic.com
Forward Looking Statements
Certain information set forth in this news release may contain forward-looking statements that involve substantial known and unknown risks and uncertainties. All statements other than statements of historical fact are forward-looking statements, including, without limitation, statements regarding future financial position, business strategy, use of proceeds, corporate vision, proposed acquisitions, partnerships, joint-ventures and strategic alliances and co-operations, budgets, cost and plans and objectives of or involving the Company. Such forward looking information reflects management's current beliefs and is based on information currently available to management. Often, but not always, forward-looking statements can be identified by the use of words such as "plans", "expects", "is expected", "budget", "scheduled", "estimates", "forecasts", "predicts", "intends", "targets", "aims", "anticipates" or "believes" or variations (including negative variations) of such words and phrases or may be identified by statements to the effect that certain actions "may", "could", "should", "would", "might" or "will" be taken, occur or be achieved. A number of known and unknown risks, uncertainties and other factors may cause the actual results or performance to materially differ from any future results or performance expressed or implied by the forward-looking information. These forward – looking statements are subject to numerous risks and uncertainties, certain of which are beyond the control of the Company including, but not limited to, the impact of general economic conditions, industry conditions and dependence upon regulatory approvals. Readers are cautioned that the assumptions used in the preparation of such information, although considered reasonable at the time of preparation, may prove to be imprecise and, as such, undue reliance should not be placed on forward-looking statements. The Company does not assume any obligation to update or revise its forward-looking statements, whether as a result of new information, future events, or otherwise, except as required by securities laws.
Copyright (c) 2024 TheNewswire - All rights reserved.
News Provided by TheNewsWire via QuoteMedia
Apple introduces groundbreaking health features to support conditions impacting billions of people
Apple Watch delivers new sleep apnea notifications, and AirPods Pro 2 provide the world's first all-in-one hearing health experience including a clinical-grade, over-the-counter Hearing Aid feature
Apple® today unveiled breakthrough sleep and hearing health features coming to Apple Watch ® and AirPods Pro® 2 that further deliver on Apple's commitment to health with experiences that enrich users' lives. These new features expand across products, bringing informative and powerful ways to support users in their sleep and hearing health for conditions that impact billions globally.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20240909409417/en/
Apple introduces groundbreaking new features across sleep and hearing health. (Photo: Business Wire)
Using an innovative new Breathing Disturbances metric, sleep apnea notifications come to Apple Watch, adding to the many ways Apple Watch acts as an intelligent guardian for users' health. The sleep apnea notifications are expected to receive marketing authorization from the Food and Drug Administration (FDA) and other global health authorities soon, with availability this month in more than 150 countries and regions, including the U.S., the EU, and Japan. 1
Apple is providing the world's first all-in-one hearing health experience with AirPods Pro with active Hearing Protection 2 , a clinically validated Hearing Test feature, and an over-the-counter Hearing Aid feature. The first-of-its-kind software-based Hearing Aid feature helps make access to hearing assistance easier than ever at an approachable price point. The Hearing Test and Hearing Aid features are expected to receive marketing authorization from global health authorities soon, and will be available this fall in more than 100 countries and regions, including the U.S., Germany, and Japan. 3
"At Apple, we believe that technology can help you live a healthier life, and we're excited to enable incredible new health capabilities for serious conditions that affect billions of people around the world, while continuing to keep user data private," said Sumbul Desai, M.D., Apple's vice president of Health. "With Apple Watch, we continue to offer our users the ability to uncover important health conditions with new sleep apnea notifications. And on AirPods Pro, powerful features put users' hearing health front and center, bringing new ways to help test for and receive assistance for hearing loss."
A Powerful Way to Detect Signs of Sleep Apnea
Sleep is an important area of health as it impacts a person's overall physical and mental wellbeing. Sleep apnea is a prevalent disorder in which breathing momentarily stops during sleep, preventing the body from getting enough oxygen. The condition is estimated to impact more than 1 billion people worldwide, and in most cases, goes undiagnosed. If left untreated, it can have important health consequences over time, including increased risk of hypertension, type 2 diabetes, and cardiac issues.
Breathing Disturbances is an innovative new Apple Watch metric that uses the accelerometer to detect small movements at the wrist associated with interruptions to normal respiratory patterns during sleep. Every 30 days, Apple Watch will analyze breathing disturbance data and notify users if it shows consistent signs of moderate to severe sleep apnea so they can speak to their doctor about next steps, including potential diagnosis and treatment.
Because overall quality of sleep is important, Breathing Disturbances can also be used to assess restfulness of sleep. Breathing Disturbances can be influenced by alcohol, medications, sleep position, and more. Users can view their nightly Breathing Disturbances in the Health app, where they are classified as elevated or not elevated, and can be viewed over a one-month, six-month, or one-year period.
For more informed conversations with their healthcare providers, users can export a PDF that shows when sleep apnea may have occurred, three months of breathing disturbance data, and additional information. Educational articles are also available within the Health app to help users learn more about sleep apnea.
The sleep apnea notification algorithm was developed using advanced machine learning and an extensive data set of clinical-grade sleep apnea tests. The feature was then validated in a clinical study — unprecedented in size for sleep apnea technology. In the clinical validation study, every participant identified by the algorithm had at least mild sleep apnea.
"Empowering consumers everywhere to have the ability to reliably identify the presence of abnormal breathing patterns during sleep can help uncover a woefully underdiagnosed and serious medical condition such as sleep apnea," said Sairam Parthasarathy, M.D., University of Arizona Health Sciences Center for Sleep, Circadian, and Neurosciences's professor and director in Tucson, Arizona. "This is a major step forward in improving public health."
Sleep apnea notifications and Breathing Disturbances add to a range of sleep health features for Apple Watch users. In addition to monitoring important overnight health metrics like heart rate and respiratory rate, Apple Watch also helps users meet their sleep goals and track their sleep over time.
The World's First All-in-One Hearing Health Experience
Approximately 1.5 billion people around the world are living with hearing loss, according to the World Health Organization. Research has also identified links between hearing loss and impact on a person's overall wellbeing, including dementia and social isolation.
To help users better understand their hearing health, Apple is introducing an end-to-end experience focused on prevention, awareness, and assistance.
Prevention
According to the Apple Hearing Study — a virtual longitudinal public research study conducted in collaboration with the University of Michigan School of Public Health and the World Health Organization — one in three people are regularly exposed to loud environmental noise levels that can impact their hearing. That can include common scenarios like taking the subway while commuting, mowing the lawn at home, attending a sporting event, and many more.
In order to help users prevent exposure to loud environmental noise while preserving the sound signature of what they're listening to, Hearing Protection comes to AirPods Pro. The ear tips help to provide passive noise reduction, while the H2 chip helps to actively reduce louder, more intermittent noise at 48,000 times per second. On by default across all listening modes, Hearing Protection is helpful in a variety of loud settings. Plus, with an all-new multiband high dynamic range algorithm, sounds at live events like concerts remain natural and vibrant.
Awareness
Hearing loss often worsens gradually, leaving many people unaware that they may be living with the condition. Eighty percent of adults in the U.S. have not had their hearing checked in the last five years, according to the American Speech-Language-Hearing Association. To give users even more insights into hearing health, Apple is introducing an intuitive, clinical-grade hearing test based on the standard clinical approach called pure-tone audiometry that users can take themselves with their AirPods Pro and a compatible iPhone® or iPad®.
Users can take the convenient test in about five minutes from the comfort of their own home. The Hearing Test feature leverages advanced acoustic science and provides users with an interactive experience. When a user completes the test, they will see an easy-to-understand summary of their results, including a number representing hearing loss in each ear, a classification, and recommendations. The results, which include an audiogram, are stored privately and securely in the Health app, and can be shared with a healthcare provider to have more informed conversations.
The Hearing Test builds on learnings from the Apple Hearing Study and was developed using large-scale, real-world data. The feature was then validated against the clinical gold standard of pure-tone audiometry.
"Hearing health is a cornerstone of overall wellbeing. Protecting and preserving our hearing enhances our quality of life both in the short-term and long-term," said Rick Neitzel, University of Michigan School of Public Health's professor of Environmental Health Sciences and principal investigator of the Apple Hearing Study. "I'm thrilled Apple is introducing important tools to support people's hearing health. These tools will help people protect their ears from noise pollution, be aware of changes in their hearing over time, and have important conversations with their healthcare providers when they need additional support."
Assistance
Learning about hearing loss is a critical step to getting necessary assistance, which can often be challenging due to cost and access. Global research shows hearing loss often goes untreated. In fact, the Apple Hearing Study revealed that 75 percent of people diagnosed with hearing loss haven't received the assistive support that they need.
AirPods Pro add an innovative over-the-counter Hearing Aid capability for users with mild to moderate hearing loss. Using the personalized hearing profile from the Hearing Test, this new feature seamlessly transforms AirPods Pro into a clinical-grade hearing aid. After setup, the feature enables personalized dynamic adjustments so users have the sounds around them boosted in real time. This helps them better engage in conversation, and keeps them connected to the people and environment around them. With the incredible audio quality of AirPods Pro, the user's personalized hearing profile is automatically applied to music, movies, games, and phone calls across their devices, without needing to adjust any settings. Users can also set up the Hearing Aid feature with an audiogram created by a hearing health professional.
The Hearing Aid feature was clinically validated in a controlled, randomized study that evaluated the perceived benefit of the feature and its custom settings compared to an audiologist-assisted setup.
After taking the Hearing Test, the user's hearing profile can also help to personalize the AirPods Pro listening experience for even more people, including those with little to no hearing loss who can still benefit from specific adjustments at individual frequencies. To help provide the best listening experience, Media Assist is an all-new feature that helps boost certain parts of speech on a phone call or instruments within a soundtrack to help an even broader population.
These features build on the hearing health tools Apple currently offers its users. For example, with the Noise app, Apple Watch users can enable notifications for when environmental noise levels might affect their hearing health. On iPhone, users can set a headphone volume limit where they can turn on Reduce Loud Audio and drag a slider to a preferred decibel level. Apple also offers additional accessibility features for users to customize settings to meet their hearing needs.
"For decades, Apple has led the way in designing products for everyone and supporting users with a broad spectrum of hearing abilities," said Sarah Herrlinger, Apple's senior director of Global Accessibility Policy and Initiatives. "These features on AirPods Pro will make an impact on so many people by driving more awareness around hearing health and empowering individuals with new customizable tools to help them stay connected."
Additional features coming to Apple Watch, iPhone, and iPad include:
- The new Vitals app on Apple Watch gives users a way to check in on their daily health status and view key overnight health metrics, like heart rate and respiratory rate, and gain better context when it comes to their health.
- The Health app offers additional support for pregnant users to reflect changes in their physical and mental health during this important time. Users can view the current gestational age and log symptoms in Cycle Tracking. Apple Watch users can also receive recommendations to review features like high heart rate notifications.
- Time spent journaling can be saved as mindful minutes in the Health app, and users can log their state of mind right in Journal.
Since launching the Health app in 2014, Apple has introduced meaningful features that focus on 18 areas of health and fitness across Apple Watch, AirPods®, iPhone, and iPad. Apple is committed to empowering users on their health journey by building actionable features into the products they use every day that are grounded in science, and have privacy at the core.
Built with Privacy at the Core
Privacy is fundamental in the design and development across all of Apple's health features. When a user's device is locked with a passcode, Touch ID®, or Face ID®, all of their health and fitness data in the Health app — other than Medical ID — is encrypted. Any Health data backed up to iCloud® is encrypted both in transit and on Apple servers. When using iOS, iPadOS®, and watchOS® with the default two-factor authentication and a passcode, Health app data synced to iCloud is encrypted end-to-end, meaning that Apple does not have the key to decrypt the data and therefore cannot read it.
Availability
- Some features may not be available in all regions or all languages, or with all makes and models.
- The sleep apnea notifications are expected to receive marketing authorization from the FDA and other global health authorities soon, with availability this month in more than 150 countries and regions, including the U.S. , the EU , and Japan . The feature will be supported on Apple Watch Series 9, Apple Watch Series 10, and Apple Watch Ultra® 2.
- The Hearing Test and Aid features are expected to receive marketing authorization from global health authorities soon and will be supported with AirPods Pro 2 with the latest firmware when paired with a compatible iPhone or iPad, and will be available this fall in more than 100 countries and regions, including the U.S ., Germany , and Japan .
- The Hearing Protection feature is expected to be available in fall 2024 and will work with AirPods Pro 2 with the latest firmware when paired with a compatible iPhone, iPad, or Mac® running the latest operating system. The feature will be available in the U.S. and Canada .
Apple revolutionized personal technology with the introduction of the Macintosh in 1984. Today, Apple leads the world in innovation with iPhone, iPad, Mac, AirPods, Apple Watch, and Apple Vision Pro. Apple's six software platforms — iOS, iPadOS, macOS, watchOS, visionOS, and tvOS — provide seamless experiences across all Apple devices and empower people with breakthrough services including the App Store, Apple Music, Apple Pay, iCloud, and Apple TV+. Apple's more than 150,000 employees are dedicated to making the best products on earth and to leaving the world better than we found it.
1 The sleep apnea notification feature is pending FDA clearance and is expected to be available later this month. The feature will be supported on Apple Watch Series 9, Apple Watch Series 10, and Apple Watch Ultra 2. It is intended to detect signs of moderate to severe sleep apnea for people 18 years or older without a diagnosis of sleep apnea.
2 The Hearing Protection feature works with AirPods Pro 2 with the latest firmware when paired with a compatible iPhone, iPad, or Mac running the latest operating system. The feature will be available in the U.S. and Canada. See support.apple.com/120850 for total attenuation and more information.
3 The Hearing Test and Hearing Aid features are expected to be available fall 2024. The Hearing Aid feature is pending marketing authorization from the FDA and other global health authorities. The Hearing Test and Hearing Aid features will be supported on AirPods Pro 2 with the latest firmware paired with a compatible iPhone or iPad with iOS 18 or iPadOS 18 and later, and is intended for people 18 years or older. The Hearing Aid feature is intended for people with perceived mild to moderate hearing loss.
NOTE TO EDITORS: For additional information visit Apple Newsroom ( www.apple.com/newsroom ), or email Apple's Media Helpline at media.help@apple.com .
© 2024 Apple Inc. All rights reserved. Apple, the Apple logo, Apple Watch, AirPods Pro, iPhone, iPad, AirPods, Touch ID, Face ID, iCloud, iPadOS, watchOS, Apple Watch Ultra, and Mac are trademarks of Apple. Other company and product names may be trademarks of their respective owners.
View source version on businesswire.com: https://www.businesswire.com/news/home/20240909409417/en/
Zaina Khachadourian
Apple
zkhachadourian@apple.com
Lance Lin
Apple
lance_lin@apple.com
News Provided by Business Wire via QuoteMedia
Latest News
Latest Press Releases
Related News
TOP STOCKS
Investing News Network websites or approved third-party tools use cookies. Please refer to the cookie policy for collected data, privacy and GDPR compliance. By continuing to browse the site, you agree to our use of cookies.